Biovica International AB (publ) (FRA:9II)

Market Cap	9.22M +42.1%
Revenue (ttm)	1.23M +54.7%
Net Income	-6.43M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0020
Previous Close	0.0024
Day's Range	0.0020 - 0.0020
52-Week Range	0.0002 - 0.0538
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 17, 2026

About Biovica International AB

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9II

Financial Performance

In fiscal year 2026, Biovica International AB's revenue was 13.38 million, an increase of 54.74% compared to the previous year's 8.65 million. Losses were -69.86 million, -20.27% less than in 2025.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error